Market Cap
US$1.7b
Last Updated
2021/01/22 00:57 UTC
Data Sources
Company Financials +
Executive Summary
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. More Details
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Similar Companies
Share Price & News
How has Precigen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: PGEN's weekly volatility has decreased from 23% to 16% over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
6.2%
PGEN
0.7%
US Biotechs
1.4%
US Market
1 Year Return
54.9%
PGEN
40.9%
US Biotechs
22.6%
US Market
Return vs Industry: PGEN exceeded the US Biotechs industry which returned 41.5% over the past year.
Return vs Market: PGEN exceeded the US Market which returned 22.8% over the past year.
Shareholder returns
| PGEN | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.2% | 0.7% | 1.4% |
| 30 Day | -13.0% | 5.2% | 4.9% |
| 90 Day | 108.2% | 23.7% | 14.6% |
| 1 Year | 54.9%54.9% | 43.2%40.9% | 25.4%22.6% |
| 3 Year | -37.7%-37.7% | 27.1%20.5% | 46.8%37.0% |
| 5 Year | -68.5%-68.5% | 58.4%46.0% | 132.0%106.1% |
Long-Term Price Volatility Vs. Market
How volatile is Precigen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Does Precigen (NASDAQ:PGEN) Have A Healthy Balance Sheet?2 months ago | Simply Wall St
A Look At Precigen's (NASDAQ:PGEN) Share Price Returns3 months ago | Simply Wall St
Is Precigen, Inc.'s (NASDAQ:PGEN) Shareholder Ownership Skewed Towards Insiders?Valuation
Is Precigen undervalued compared to its fair value and its price relative to the market?
27.9x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PGEN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PGEN is overvalued based on its PB Ratio (27.9x) compared to the US Biotechs industry average (4.5x).
Next Steps
Future Growth
How is Precigen forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
26.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PGEN's revenue (10.5% per year) is forecast to grow slower than the US market (10.5% per year).
High Growth Revenue: PGEN's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PGEN is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Precigen performed over the past 5 years?
-18.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PGEN is currently unprofitable.
Growing Profit Margin: PGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PGEN is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare PGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: PGEN has a negative Return on Equity (-301.1%), as it is currently unprofitable.
Next Steps
Financial Health
How is Precigen's financial position?
Financial Position Analysis
Short Term Liabilities: PGEN's short term assets ($151.1M) exceed its short term liabilities ($30.7M).
Long Term Liabilities: PGEN's short term assets ($151.1M) do not cover its long term liabilities ($247.0M).
Debt to Equity History and Analysis
Debt Level: PGEN's debt to equity ratio (331.7%) is considered high.
Reducing Debt: PGEN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PGEN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PGEN has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 28.9% each year.
Next Steps
Dividend
What is Precigen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
8.2yrs
Average management tenure
CEO
Helen Sabzevari (58 yo)
1
Tenure
US$1,465,107
Compensation
Dr. Helen Sabzevari, Ph.D., MPH, has been President and Chief Executive Officer of Precigen, Inc (formerly Intrexon Corporation) since January 2, 2020 and has been its Director since June 19, 2020. He serv...
CEO Compensation Analysis
Compensation vs Market: Helen's total compensation ($USD1.47M) is below average for companies of similar size in the US market ($USD3.86M).
Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 12.92yrs | US$2.07m | 9.46% $ 160.4m | |
| President | 1yr | US$1.47m | 0.35% $ 6.0m | |
| Chief Financial Officer | 14yrs | US$1.50m | 0.18% $ 3.1m | |
| Chief Legal Officer & Corporate Secretary | 10yrs | US$1.56m | 0.15% $ 2.5m | |
| Senior Vice President of Intellectual Property Affairs | 6.42yrs | US$1.48m | 0.15% $ 2.6m | |
| Founder & Chief Science Officer | 23yrs | US$572.72k | 0.14% $ 2.3m | |
| Head of Operations & Portfolio | no data | no data | no data | |
| Head of Investor Relations | 3yrs | no data | no data | |
| Vice President of Communications | no data | no data | no data | |
| Head of Human Resources | no data | no data | no data | |
| Head of Financial Strategy | no data | no data | no data | |
| Head of Research | no data | no data | no data |
8.2yrs
Average Tenure
56yo
Average Age
Experienced Management: PGEN's management team is seasoned and experienced (8.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 12.92yrs | US$2.07m | 9.46% $ 160.4m | |
| President | 1yr | US$1.47m | 0.35% $ 6.0m | |
| Independent Director | 9.17yrs | US$319.00k | 0.077% $ 1.3m | |
| Independent Director | 4.58yrs | US$306.50k | 0.046% $ 778.4k | |
| Independent Director | 12.92yrs | US$312.50k | 0.099% $ 1.7m | |
| Lead Independent Director | no data | US$312.99k | 0.11% $ 1.9m | |
| Independent Director | 6.75yrs | US$312.49k | 0.048% $ 819.1k | |
| Independent Director | 11.83yrs | US$306.50k | 0.057% $ 963.7k | |
| Independent Director | 12.92yrs | US$299.99k | 0.14% $ 2.4m | |
| Independent Director | 3.75yrs | US$306.50k | 0.044% $ 743.1k |
9.2yrs
Average Tenure
64.5yo
Average Age
Experienced Board: PGEN's board of directors are considered experienced (9.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14%.
Top Shareholders
Company Information
Precigen, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Precigen, Inc.
- Ticker: PGEN
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.695b
- Shares outstanding: 185.46m
- Website: https://www.precigen.com
Number of Employees
Location
- Precigen, Inc.
- 20374 Seneca Meadows Parkway
- Germantown
- Maryland
- 20876
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PGEN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Aug 2013 |
| I5X | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Aug 2013 |
Biography
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 00:57 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.